vs
Side-by-side financial comparison of KFORCE INC (KFRC) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $330.4M, roughly 1.9× KFORCE INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.4%, a 32.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 0.1%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -3.7%).
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
KFRC vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $330.4M | $622.0M |
| Net Profit | $7.9M | $214.2M |
| Gross Margin | 27.3% | — |
| Operating Margin | 3.6% | 62.4% |
| Net Margin | 2.4% | 34.4% |
| Revenue YoY | 0.1% | 4.8% |
| Net Profit YoY | -2.7% | 2.9% |
| EPS (diluted) | $0.46 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $622.0M | ||
| Q3 25 | $332.6M | $609.3M | ||
| Q2 25 | $334.3M | $578.7M | ||
| Q1 25 | $330.0M | $568.2M | ||
| Q4 24 | $343.8M | $593.6M | ||
| Q3 24 | $353.3M | $564.7M | ||
| Q2 24 | $356.3M | $537.3M |
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $214.2M | ||
| Q3 25 | $11.1M | $288.2M | ||
| Q2 25 | $10.4M | $30.2M | ||
| Q1 25 | $8.1M | $238.3M | ||
| Q4 24 | $11.1M | $208.2M | ||
| Q3 24 | $14.2M | $544.0M | ||
| Q2 24 | $14.2M | $102.0M |
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | — | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 27.1% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 27.8% | — |
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | 62.4% | ||
| Q3 25 | 4.5% | 70.1% | ||
| Q2 25 | 4.5% | 36.3% | ||
| Q1 25 | 3.5% | 94.0% | ||
| Q4 24 | 4.5% | 60.9% | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 5.5% | 50.2% |
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | 34.4% | ||
| Q3 25 | 3.3% | 47.3% | ||
| Q2 25 | 3.1% | 5.2% | ||
| Q1 25 | 2.5% | 41.9% | ||
| Q4 24 | 3.2% | 35.1% | ||
| Q3 24 | 4.0% | 96.3% | ||
| Q2 24 | 4.0% | 19.0% |
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $0.49 | ||
| Q3 25 | $0.63 | $0.67 | ||
| Q2 25 | $0.59 | $0.07 | ||
| Q1 25 | $0.45 | $0.55 | ||
| Q4 24 | $0.60 | $0.46 | ||
| Q3 24 | $0.75 | $1.21 | ||
| Q2 24 | $0.75 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $117.4M | $9.7B |
| Total Assets | $384.8M | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $618.7M | ||
| Q3 25 | $1.3M | $938.9M | ||
| Q2 25 | $2.5M | $631.9M | ||
| Q1 25 | $444.0K | $1.1B | ||
| Q4 24 | $349.0K | $929.0M | ||
| Q3 24 | $127.0K | $950.1M | ||
| Q2 24 | $110.0K | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $9.7B | ||
| Q3 25 | $132.1M | $9.6B | ||
| Q2 25 | $134.4M | $9.5B | ||
| Q1 25 | $138.0M | $9.8B | ||
| Q4 24 | $154.6M | $10.3B | ||
| Q3 24 | $167.4M | $10.3B | ||
| Q2 24 | $166.6M | $9.8B |
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $19.6B | ||
| Q3 25 | $374.2M | $19.3B | ||
| Q2 25 | $373.6M | $18.3B | ||
| Q1 25 | $368.2M | $17.6B | ||
| Q4 24 | $357.8M | $18.2B | ||
| Q3 24 | $369.9M | $18.0B | ||
| Q2 24 | $362.7M | $17.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | $-7.4M | — |
| FCF MarginFCF / Revenue | -2.2% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $43.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | $827.1M | ||
| Q3 25 | $23.3M | $702.6M | ||
| Q2 25 | $18.4M | $364.0M | ||
| Q1 25 | $249.0K | $596.1M | ||
| Q4 24 | $21.8M | $742.5M | ||
| Q3 24 | $31.0M | $703.6M | ||
| Q2 24 | $20.9M | $658.2M |
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $20.9M | — | ||
| Q3 24 | $27.5M | — | ||
| Q2 24 | $17.8M | — |
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | -1.2% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 5.0% | — |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | 3.86× | ||
| Q3 25 | 2.11× | 2.44× | ||
| Q2 25 | 1.76× | 12.06× | ||
| Q1 25 | 0.03× | 2.50× | ||
| Q4 24 | 1.97× | 3.57× | ||
| Q3 24 | 2.18× | 1.29× | ||
| Q2 24 | 1.48× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KFRC
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
